# IndyGeneUS AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indygeneus-ai

- Industry: Biotechnology
- Headquarters: Washington, US
- Website: www.indygeneus.ai
- Total disclosed funding: $1.5M
- Latest round: Seed (Nov 15, 2021)
- Investors on record: 1

## About

IndyGeneUS AI focuses on precision medicine, developing advanced therapeutics and gene therapies to address health disparities within African diaspora populations using artificial intelligence.IndyGeneUS AI, headquartered in Washington, US, was founded in 2020 by Bradford Wilson and Yusuf Henriques. The company is recognized for its innovative approach in precision medicine and has secured a total amount of USD 1.500 mn through various funding rounds, including the most recent GRANT of USD 0.180 mn received on May 12, 2022, from Johnson & Johnson Innovation. To date, the company has completed 2 significant deals.IndyGeneUS AI specializes in precision medicine through the development and manufacturing of advanced therapeutics, particularly in gene and cell therapies. The company operates as a Contract Development and Manufacturing Organization (CDMO), offering services such as analytical development, viral vector manufacturing, and cell therapy bioprocessing. Their core product offerings enable the creation of targeted therapies aimed at diminishing health disparities faced by African diaspora populations. Through the application of artificial intelligence and data mining, IndyGeneUS AI helps clients expedite the product life cycle from pre-clinical stages to commercial manufacturing, serving a diverse client base that spans biopharmaceutical firms, research institutions, and healthcare providers, particularly in North America and Europe.IndyGeneUS AI generates revenue primarily from business-to-business transactions with biopharmaceutical companies and research institutions, assisting in the development and commercialization of advanced therapies. The company operates on a contractual basis, providing tailored services at various development stages. Their flagship product, the IndyGeneUS-IQ™ Kit, contributes to the revenue stream, with pricing structures established based on the complexity of each project.IndyGeneUS AI plans to utilize the recent funding of USD 0.180 mn from Johnson & Johnson Innovation to further develop and launch new products in the precision medicine sector. The company aims to expand its market presence in Europe and other international regions by the end of 2023. Specifically, they are focusing on enhancing their service offerings in gene therapies and expanding collaborations with healthcare institutions to better address health disparities.

## Funding rounds

- Seed, Nov 15, 2021, $1.5M — IsimoVest Venture Capital Partners

## Investors

- IsimoVest Venture Capital Partners (https://capitalatlas.ai/funds/isimovest-venture-capital-partners) — Seed